Details of the Drug Combination

General Information of Drug Combination (ID: DCVJBT7)

Drug Combination Name
Trioxsalen Valproic Acid
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Trioxsalen   DM53BDW Valproic Acid   DMS49KH
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 4.09
Bliss Independence Score: 4.09
Loewe Additivity Score: 18.15
LHighest Single Agent (HSA) Score: 18.15

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Trioxsalen FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Valproic Acid FDA Label
5 Immunopharmacological management of COVID-19: Potential therapeutic role of valproic acid. Med Hypotheses. 2020 May 27;143:109891.